Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 20/20 | 1.00 |
| ▸ | MAOA | P21397 | 19/20 | 1.00 |
| ▸ | NPC1 | O15118 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | HPGD | P15428 | 1/20 | 0.56 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.56 |
| ▸ | GRM5 | P41594 | 1/20 | 0.56 |
| ▸ | RAB9A | P51151 | 1/20 | 0.56 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.56 |
| ▸ | RELA | Q04206 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3501723 | 1.00 | MAOB (1.00) | MAOBMAOANPC1ALDH1A1HPGD | |
| SCHEMBL7215662 | 0.97 | MAOB (0.94) | MAOBMAOANPC1ALDH1A1HPGD | |
| SCHEMBL2524800 | 0.91 | MAOB (0.84) | MAOBMAOANPC1ALDH1A1HPGD | |
| SCHEMBL30353268 | 0.91 | MAOB (0.84) | MAOBMAOANPC1ALDH1A1HPGD | |
| SCHEMBL7218099 | 0.91 | MAOB (0.82) | MAOBMAOANPC1ALDH1A1HPGD | |
| SCHEMBL226640 | 0.89 | MAOB (1.00) | MAOBMAOANPC1ALDH1A1HPGD | |
| SCHEMBL6309072 | 0.86 | MAOB (1.00) | MAOBMAOA | |
| SCHEMBL7184607 | 0.86 | MAOA (0.76) | MAOBMAOANPC1RAB9A | |
| SCHEMBL15414670 | 0.86 | MAOB (0.81) | MAOBMAOA | |
| SCHEMBL3451690 | 0.86 | MAOB (0.94) | MAOBMAOANPC1ALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122074043-A | Combination therapy with KRAS modulators | 光达治疗公司 | 2026-05-22 | — | — | CN | disclosed |
| WO-2025034883-A1 | COMBINATION THERAPIES WITH KRAS MODULATORS | QUANTA THERAPEUTICS, INC. (US) | 2025-02-13 | — | — | WO | disclosed |
| WO-2025034919-A1 | COMBINATION THERAPIES WITH KRAS MODULATORS | QUANTA THERAPEUTICS, INC. (US) | 2025-02-13 | — | — | WO | disclosed |
| EP-4475956-A1 | KRAS MODULATORS AND USES THEREOF | Quanta Therapeutics, Inc. (US) | 2024-12-18 | — | — | EP | disclosed |
| CN-119110804-A | KRAS modulators and uses thereof | 光达治疗公司 | 2024-12-10 | — | — | CN | disclosed |
| WO-2023154766-A1 | KRAS MODULATORS AND USES THEREOF | QUANTA THERAPEUTICS, INC. (US) | 2023-08-17 | — | — | WO | disclosed |
| WO-2022240971-A2 | KRAS G12D INHIBITORS AND USES THEREOF | 1200 PHARMA LLC (US) | 2022-11-17 | — | — | WO | disclosed |